Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company reported better-than-expected performance in Q4 2024, with a focus on optimizing the supply chain for its plant protection business [5][6]. - The company's revenue for 2024 was 5.68 billion yuan, a decrease of 11.88% year-on-year, but it achieved a net profit of 103 million yuan, marking a return to profitability [5][6]. - The plant protection business experienced a revenue decline due to falling pesticide prices, but gross margins improved due to technological innovation and management optimization [6][7]. - The company is expanding its supply chain layout with a new production base in Malaysia, enhancing its service offerings across the product lifecycle [7]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 1.32 billion yuan, down 7.44% year-on-year, but net profit reached 70.64 million yuan, a significant increase of 285% quarter-on-quarter [5]. - For Q1 2025, revenue was 1.51 billion yuan, up 3.02% year-on-year and 14.55% quarter-on-quarter, with a net profit of 49.72 million yuan, reflecting a year-on-year growth of 1747% [5]. Business Segments - The pharmaceutical segment generated 1.29 billion yuan in revenue, down 13.3% year-on-year, but gross margin improved by 13.1 percentage points to 48.0% [6]. - The plant protection segment had a revenue of 3.59 billion yuan, down 15.4% year-on-year, with a gross margin increase of 5.8 percentage points to 20.1% [6]. Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 305 million yuan, 415 million yuan, and 536 million yuan respectively, reflecting a positive outlook based on industry recovery and improved margins [8][9]. - The report highlights the company's ongoing projects in the pharmaceutical sector, including six validation projects, with a focus on API and innovative drug intermediates [7][8].

Group 1: Company Operations and Performance - The UK factory's annual capacity utilization rate is increasing, and it is expected to improve its operating conditions in 2025 [1][3] - The Malaysian factory is currently in the construction phase, with future investments dependent on order conditions [1][3] - The company has achieved profitability in the first quarter of 2025 due to exchange gains from the UK subsidiary [2][3] Group 2: Market and Strategic Outlook - The company does not currently plan any mergers or strategic partnerships to overcome market bottlenecks [1] - The company focuses on business expansion, R&D, and project construction to enhance value and protect shareholder interests [2] - The company anticipates steady growth across its business segments in 2025, particularly in plant protection, pharmaceuticals, and functional chemicals [2][3] Group 3: Financial Management and Shareholder Value - The company is implementing a valuation enhancement plan that includes operational improvements, investor relations management, and cash dividends [3] - Measures to manage market volatility and enhance shareholder returns include share buybacks and employee stock ownership plans [3] - The company aims to maintain compliance with environmental regulations while promoting sustainable development [4] Group 4: Environmental and Sustainability Initiatives - The company has been disclosing its sustainability management efforts for four consecutive years and is implementing a greenhouse gas inventory system [3][4] - Future plans include the gradual implementation of carbon reduction strategies to achieve carbon neutrality [4] - All projects are constructed in accordance with environmental protection requirements, ensuring compliance with national regulations [4]

Group 1: Impact of Tariff Policies - The impact of US-China tariff policies on the company's operations is limited, as the export business to the US accounts for a small proportion and most products are on the exemption list [1] - The company has no procurement of raw materials or equipment from the US, and it maintains communication with customers regarding supply chain stability and tax optimization in response to tariff changes [1] Group 2: Financial Performance - In Q1 2025, the company experienced improved operational performance, benefiting from increased foreign exchange gains and a turnaround in derivatives from loss to profit compared to Q1 2024, leading to a significant rise in net profit [1] - The competitive landscape in the new energy sector is intense, with some pressure on performance due to the transition of production lines to fixed assets and depreciation [1] - The company anticipates a breakthrough in revenue from its new energy business in 2025 [2] Group 3: Pharmaceutical Business Development - The pharmaceutical business is progressing as planned, with expectations for growth in 2025, focusing on major clients, primarily European pharmaceutical companies [2] - The company is enhancing existing partnerships while simultaneously developing new clients and strengthening R&D capabilities [2] Group 4: New Energy Business Progress - The new energy business is advancing with ongoing customer communication, project R&D, and quality system development [2] - The company is entering the new energy sector with products like electrolytes, aiming for revenue breakthroughs in 2025 [2] Group 5: Overseas Factory Performance - The UK factory is expected to see improved operational performance in 2025, with a rise in capacity utilization and profitability achieved in Q1 2025 due to foreign exchange gains [3][4] - The Malaysian factory is still in the construction phase, with investment progress contingent on order situations [4]

Financial Performance - The company's revenue for Q1 2025 was CNY 1,509,820,847.64, representing a 3.02% increase compared to CNY 1,465,597,404.32 in the same period last year[5] - Net profit attributable to shareholders reached CNY 49,715,553.49, a significant increase of 1,747.04% from CNY 2,691,631.55 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 47,786,202.06, up 318.63% from CNY 11,415,035.96 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.0546, reflecting a 1,720.00% increase from CNY 0.003 in the previous year[5] - Operating profit increased to ¥96,419,913.66, up 79.4% from ¥53,856,081.75 in the prior period[18] - Net profit for the current period was ¥69,884,038.49, representing a significant increase of 188.5% compared to ¥24,235,708.40 from the previous period[18] Cash Flow - The net cash flow from operating activities was CNY 9,723,372.25, an increase of 141.53% compared to CNY 4,025,709.35 in the same period last year[5] - Cash flow from operating activities generated a net amount of ¥9,723,372.25, a substantial increase from ¥4,025,709.35 in the last period[19] - Investment activities resulted in a net cash outflow of ¥108,490,185.06, an improvement from a larger outflow of ¥264,620,183.35 in the prior period[19] - Net cash flow from financing activities was -$113.56 million, compared to $321.45 million in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,685,205,233.59, a decrease of 0.80% from CNY 13,795,078,251.29 at the end of the previous year[5] - Total liabilities were CNY 6,836,840,997.86, down from CNY 6,918,771,100.14[15] - Current assets totaled CNY 5,561,061,381.99, showing a slight increase from CNY 5,456,943,622.05[14] - The company's cash and cash equivalents decreased to CNY 1,007,375,287.30 from CNY 1,202,166,591.32[14] - Accounts receivable rose to CNY 1,499,783,951.05 from CNY 1,225,529,334.94, indicating a significant increase[14] - Inventory decreased to CNY 2,397,206,767.43 from CNY 2,454,145,542.26, reflecting a reduction in stock levels[14] - The non-current assets totaled CNY 8,124,143,851.60, down from CNY 8,338,134,629.24[15] Shareholder Information - Shareholders' equity attributable to the parent company was CNY 6,425,823,472.81, down 0.74% from CNY 6,473,934,873.23 at the end of the previous year[5] - The company reported a decrease in total equity to CNY 6,848,364,235.73 from CNY 6,876,307,151.15[16] - The total number of ordinary shareholders at the end of the reporting period was 38,284[10] Expenses - Financial expenses decreased by 60.86% to CNY 15,796,285.38, primarily due to increased exchange gains compared to the previous year[8] - Total operating costs rose to ¥1,408,599,103.79, an increase of 1.8% from ¥1,385,254,663.45 in the previous period[17] - Research and development expenses were ¥74,406,430.75, slightly up from ¥72,185,914.55 in the prior period[17] Other Information - Other comprehensive income after tax showed a loss of ¥17,830,315.91, compared to a gain of ¥1,735,453.81 in the previous period[18] - The company disposed of fixed assets, generating cash inflow of ¥10,000,000.00, with no comparable inflow in the previous period[19] - Cash and cash equivalents at the end of the period totaled $779.39 million, down from $656.60 million year-over-year[20] - The impact of exchange rate changes on cash and cash equivalents was $4.29 million, compared to -$139,708.12 in the previous period[20] - The company did not pay dividends or profits to minority shareholders during the reporting period[20] - The first quarter report was not audited[21] - The company will implement new accounting standards starting from 2025[22]

Core Insights - Despite an 11.88% year-on-year decline in revenue to 5.677 billion yuan, the company achieved a significant profit rebound, with total profit increasing by 159.94% to 241 million yuan and net profit attributable to shareholders rising by 122.17% to 103 million yuan, successfully reversing previous losses [1] - The company aims to become a global leader in chemical and technology solutions, focusing on differentiated development and enhancing core competitiveness through a strategy of "focus, foresight, and alliances" [1] Business Segments - The crop protection segment remains the core pillar, contributing 3.590 billion yuan, accounting for 63.25% of total revenue. The company has established a supply chain system covering the entire product lifecycle through its production bases in China, the UK, and Malaysia [2] - The pharmaceutical CDMO segment generated revenue of 1.285 billion yuan, benefiting from the growing demand for outsourced R&D in innovative drugs. The company has formed partnerships with several leading pharmaceutical firms and is expanding its CRO platform [2] Future Strategy - The company plans to expand mature businesses, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials. It will also invest in emerging businesses such as peptide CDMO and radioactive drug-related CDMO [3] - Despite revenue pressures, the company maintains a strong commitment to R&D, with R&D expenses reaching 291 million yuan, accounting for 5.13% of revenue. The company holds 160 domestic and international invention patents [3] International Strategy - The company's overseas strategy is proactive, with the UK base serving as a gateway to the European market and the Malaysian project as a key foothold in Southeast Asia. This multi-regional capacity configuration reduces geopolitical risks and allows for customized solutions based on client needs [3] Shareholder Returns - The company returned nearly 98 million yuan to shareholders through cash dividends and share buybacks, representing 94.84% of net profit, demonstrating management's commitment to investor returns [4] - The company has implemented a mechanism for shared interests between shareholders and employees, binding core talent through capital increases and employee stock ownership plans [4] Outlook - The company is positioned for a higher quality leap as a "chemical solutions provider," warranting continued market attention [5]

联化科技股份有限公司 独立董事2024年度述职报告 ——Zhang Yun 作为联化科技股份有限公司（以下简称"公司"或"联化科技"）第八届董事会 独立董事，本人根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等法律、法规以及《公司章程》、《独立董事制度》的相关规 定，在2024年度充分发挥独立董事的监督作用，忠实履行各项职责，积极出席相关会 议，并以谨慎的态度对相关议案发表了表决意见，维护了公司的整体利益和中小股东 的合法利益。现将2024年度工作述职如下： 一、基本情况 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关法律 法规中对独立董事独立性的相关要求，不存在影响独立性的情况。 二、2024年度履职情况 2024年度，本人认真参加了公司的董事会和股东大会，履行了独立董事勤勉尽 责义务。具体出席会议情况如下： | | 独立董事出席董事会情况 | | | | | | --- | --- | --- | --- | --- | --- | | 独立董事姓名 会召开次数 | 本报告期董 ...

联化科技股份有限公司董事会 2025 年 4 月 23 日 联化科技股份有限公司董事会 关于独立董事保持独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第1 号——主板上市公司规范运作》等相关规定，联化科技股份有限公司（以下简称"公 司"）董事会就公司在任独立董事蒋萌女士、俞寿云先生、Zhang Yun先生的独立性 情况进行评估并出具如下专项意见： 经核查独立董事蒋萌女士、俞寿云先生、Zhang Yun先生的任职经历以及签署 的相关自查文件等内容，公司董事会认为上述人员未在公司担任独立董事以外的任 何职务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利害 关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性 的情况，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第1号——主板上市公司规范运作》等相关法律法规中对独立董 事独立性的相关要求。 ...

作为联化科技股份有限公司（以下简称"公司"或"联化科技"）第八届董事会 独立董事，本人根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等法律、法规以及《公司章程》、《独立董事制度》的相关规 定，在2024年度充分发挥独立董事的监督作用，忠实履行各项职责，积极出席相关会 议，并以谨慎的态度对相关议案发表了表决意见，维护了公司的整体利益和中小股东 的合法利益。现将2024年度工作述职如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 本人蒋萌，女，1980年1月出生，学士，已取得独立董事资格证书。历任山东琴 岛律师事务所项目运营及工程建设法律部专职律师、合伙人、高级合伙人，现任山 东国曜琴岛（青岛）律师事务所权益合伙人、联化科技独立董事。 2022年9月21日，公司召开的2022年第三次临时股东大会选举本人为公司第八届 董事会独立董事。 联化科技股份有限公司 独立董事2024年度述职报告 ——蒋萌 （二）不存在影响独立性的情况 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关法律 法 ...

联化科技股份有限公司 独立董事2024年度述职报告 作为联化科技股份有限公司（以下简称"公司"或"联化科技"）第八届董事会 独立董事，本人根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等法律、法规以及《公司章程》、《独立董事制度》的相关规 定，在2024年度充分发挥独立董事的监督作用，忠实履行各项职责，积极出席相关会 议，并以谨慎的态度对相关议案发表了表决意见，维护了公司的整体利益和中小股东 的合法利益。现将2024年度工作述职如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 本人俞寿云，男，1978年11月出生，博士，已取得独立董事资格证书。历任南 京大学化学化工学院副教授，现任南京大学化学化工学院教授、副院长、常州丰盛 光电科技股份有限公司独立董事、联化科技独立董事。 2022年9月21日，公司召开的2022年第三次临时股东大会选举本人为公司第八届 董事会独立董事。 （二）不存在影响独立性的情况 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关法律 法规中对独立董事独立性 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002250 证券简称：联化科技 公告编号：2025-024 联化科技股份有限公司 关于召开 2024 年度股东大会的通知 网络投票时间为：2025年6月9日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6 月9日9:15至9:25，9:30至11:30和13:00至15:00；通过深圳证券交易所互联网投票 系统投票的具体时间为：2025年6月9日9:15至15:00。 一、召开会议基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：联化科技股份有限公司（以下简称"公司"、"联化 科技"）第八届董事会第二十三次会议决议提请召开股东大会。 3、会议召开的合法、合规性：本次股东大会会议的召集、召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： 现场会议时间为：2025年6月9日（星期一）13时30分 （1）截至2025年6月3日下午收市后在中国证券登记结算公司深圳分公司登 5、会议的召开方式：本次股东大会以现场表决 ...